Effects of DL-endopeptidase Producing Probiotics on Human Intestinal NOD2 Ligands and Related Functions

Launched by ZHUJIANG HOSPITAL · Nov 28, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating how a specific type of probiotic, which produces DL-endopeptidase, can help improve gut health by repairing the intestinal barrier and managing inflammation in the intestines. Probiotics are good bacteria that can support our digestive system, and this study aims to see how effective this particular probiotic can be for people with certain gut issues.

To join the trial, participants should not have serious digestive problems, such as severe vomiting or blood in their stools, and should not have taken medications like antibiotics or probiotics in the month before the study. This trial is open to individuals of all ages and genders who are interested in participating. If you take part, you can expect to contribute to important research that could help improve treatments for intestinal health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • tend to participate the trial
• Exclusion Criteria:
• • severe digestive symptoms, such as severe vomiting, hematochezia, bloody or tarry stool within one month before intervention; antibiotics or laxatives or probiotics or intestinal antiulcer agent within one month before intervention; previous or current treatment for any diseases or illnesses such as gastrointestinal disease (gastric ulcers, Crohn's, celiac, ulcerative colitis, etc.); other chronic diseases (diabetes, kidney disease, etc.) or immunecompromising diseases or conditions (HIV/AIDS, autoimmune, hepatitis, cancer, transplant patient etc.); pregnant or lactating.